Suzetrigine, a Selective Pain Signal Inhibitor of NaV1.8 Shows Proof-of-concept for Treatment of Painful Diabetic Peripheral Neuropathy (S11.002)

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000210760
Citations
4
Primary Topic
Pain Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
4.66
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Suzetrigine, a Selective Pain Signal Inhibitor of NaV1.8 Shows Proof-of-concept for Treatment of Painful Diabetic Peripheral Neuropathy (S11.002)

Roy Freeman, Charles E. Argoff, Robert H. Dworkin, Richard Rauck et al.
4 citations
Neurology
Pain Mechanisms and Treatments
4.66
article

Suzetrigine, a Selective Pain Signal Inhibitor of NaV1.8 Shows Proof-of-concept for Treatment of Painful Diabetic Peripheral Neuropathy (S11.002)

Roy Freeman, Charles E. Argoff, Robert H. Dworkin, Richard Rauck, Simon Tian, Carmen Bozic, Xiaopeng Miao, Hannah Bouldin Olivet
article en
4 citations

Abstract

No abstract available for this paper.
NeurologyVol. 104(7_Supplement_1)
Hadassah Medical Center (IL), Carolinas Pain Institute (US), University of Rochester (US), Vertex Pharmaceuticals (United States) (US), Albany Medical Center Hospital (US)
Openalex Percentile: Top 6%
Pain Mechanisms and Treatments
4.66
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.